Non-Genomic Actions of the Androgen Receptor in Prostate Cancer
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Androgen receptor (AR) is a validated drug target for prostate cancer based on its role in proliferation, survival, and metastases of prostate cancer cells. Unfortunately, despite recent improvements to androgen deprivation therapy and the advent of better antiandrogens with a superior affinity for the AR ligand-binding domain (LBD), most patients with recurrent disease will eventually develop lethal metastatic castration-resistant prostate cancer (CRPC). Expression of constitutively active AR splice variants that lack the LBD contribute toward therapeutic resistance by bypassing androgen blockade and antiandrogens. In the canonical pathway, binding of androgen to AR LBD triggers the release of AR from molecular chaperones which enable conformational changes and protein-protein interactions to facilitate its nuclear translocation where it regulates the expression of target genes. However, preceding AR function in the nucleus, initial binding of androgen to AR LBD in the cytoplasm may already initiate signal transduction pathways to modulate cellular proliferation and migration. In this article, we review the significance of signal transduction pathways activated by rapid, non-genomic signaling of the AR during the progression to metastatic CRPC and put into perspective the implications for current and novel therapies that target different domains of AR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
Roberts, P. J., & Der, C. J. (2007) · Oncogene · doi:10.1038/sj.onc.1210422 · Cited by 2,788 · cited 1×
“EGF signaling enhances ligand-independent AR transactivation and promotes activation of Src and the Ras-Raf-MAPK/ERK pathway (9, 51, 52).”
BackgroundRyan, C. J., Smith, M. R., Fizazi, K., Saad, F., Mulders, P. F. A., Sternberg, C. N., Miller, K., Logothetis, C. J., Shore, N. D., Small, E. J., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71205-7 · Cited by 1,369
Guo, Z., Yang, X., Sun, F., Jiang, R., Linn, D. E., Chen, H., Chen, H., Kong, X., Melamed, J., Tepper, C. G., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3795 · Cited by 880
Sun, S., Sprenger, C. C. T., Vessella, R. L., Haugk, K., Soriano, K., Mostaghel, E. A., Page, S. T., Coleman, I. M., Nguyen, H. M., Sun, H., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41824 · Cited by 748 · cited 2×
“ARv567es is predominantly nuclear (64), whereas the cellular localization of V7 is more variable.”
BackgroundThe Androgen Axis in Recurrent Prostate Cancer
Mohler, J. L., Gregory, C. W., Ford, O. H., Kim, D., Weaver, C. M., Petrusz, P., Wilson, E. M., & French, F. S. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-1146-03 · Cited by 675 · cited 1×
“Levels of androgen in CRPC tissue are at least 10-fold higher, in the 1–3 nM range (59).”
BackgroundStat3 Activation by Src Induces Specific Gene Regulation and Is Required for Cell Transformation
Turkson, J., Bowman, T., Garcia, R., Caldenhoven, E., De Groot, R. P., & Jove, R. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.5.2545 · Cited by 651
Activation of the human androgen receptor through a protein kinase A signaling pathway.
Nazareth, L. V., & Weigel, N. L. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.33.19900 · Cited by 429
Akt suppresses androgen-induced apoptosis by phosphorylating and inhibiting androgen receptor.
Lin, H.-K., Yeh, S., Kang, H.-Y., & Chang, C. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.121173298 · Cited by 401
Ueda, T., Bruchovsky, N., & Sadar, M. D. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m108255200 · Cited by 381
Self-citationTargeting the PI3K/AKT Pathway for the Treatment of Prostate Cancer
Sarker, D., Reid, A. H. M., Yap, T. A., & de Bono, J. S. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0125 · Cited by 366
Regulation of androgen receptor activity by tyrosine phosphorylation.
Guo, Z., Dai, B., Jiang, T., Xu, K., Xie, Y., Kim, O., Nesheiwat, I., Kong, X., Melamed, J., Handratta, V. D., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.08.021 · Cited by 364 · cited 7×
“It is likely that an AR/Src complex is formed first by rapid signaling, followed by phosphorylation of AR Y534 by Src to recruit the p85α regulatory subunit of PI3K.”
BackgroundInfluentialUeda, T., Mawji, N. R., Bruchovsky, N., & Sadar, M. D. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m203313200 · Cited by 311 · cited 1×
“Moreover, activation of the MAPK/ERK and PI3K/ Akt kinase pathways non-genomically can enhance ligandindependent transactivation of AR by modulating interactions with coactivators including steroid receptor coactivator-1 and androgen receptor-associated protein 70 (55, 56).”
BackgroundSelf-citationMahajan, N. P., Liu, Y., Majumder, S., Warren, M. R., Parker, C. E., Mohler, J. L., Earp, H. S., & Whang, Y. E. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0700420104 · Cited by 274 · cited 7×
“It is likely that an AR/Src complex is formed first by rapid signaling, followed by phosphorylation of AR Y534 by Src to recruit the p85α regulatory subunit of PI3K.”
BackgroundInfluentialSadar, M. D. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.12.7777 · Cited by 270 · cited 1×
“Activation of AR Our lab identified that the AR NTD can be activated independently of androgen, by intracellular kinase signals, cytokines, and osteoblast-derived factors (6, 7, 49).”
BackgroundSelf-citationSmith, D. F., & Toft, D. O. (2008) · Molecular Endocrinology · doi:10.1210/me.2008-0089 · Cited by 173
Yang, L., Xie, S., Jamaluddin, M. S., Altuwaijri, S., Ni, J., Kim, E., Chen, Y.-T., Hu, Y.-C., Wang, L., Chuang, K.-H., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m504461200 · Cited by 131
Asim, M., Siddiqui, I. A., Hafeez, B. B., Baniahmad, A., & Mukhtar, H. (2008) · Oncogene · doi:10.1038/sj.onc.1211016 · Cited by 101
Functional domains of the human androgen receptor
Jenster, G., van der Korput, J. A. G. M., Trapman, J., & Brinkmann, A. O. (1992) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/0960-0760(92)90402-5 · Cited by 80 · cited 2×
“Clin Cancer Res (2014) 20(12):3198–210.”
BackgroundLiu, P., Li, S., Gan, L., Kao, T. P., & Huang, H. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-2038 · Cited by 67 · cited 1×
“Among Akt substrates, FOXO3a enhances AR expression by direct binding to the AR promoter (42), whereas FOXO1 may decrease AR transactivation by recruitment of histone deacetylase HDAC3 (43).”
BackgroundBlaszczyk, N., Masri, B. A., Mawji, N. R., Ueda, T., McAlinden, G., Duncan, C. P., Bruchovsky, N., Schweikert, H.-U., Schnabel, D., Jones, E. C., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-0974-3 · Cited by 66 · cited 1×
“Activation of AR Our lab identified that the AR NTD can be activated independently of androgen, by intracellular kinase signals, cytokines, and osteoblast-derived factors (6, 7, 49).”
BackgroundSelf-citation
Cited by
Androgen Receptor Signaling Pathway in Prostate Cancer: From Genetics to Clinical Applications
Aurilio, G., Cimadamore, A., Mazzucchelli, R., Lopez-Beltran, A., Verri, E., Scarpelli, M., Massari, F., Cheng, L., Santoni, M., & Montironi, R. (2020) · Cells · doi:10.3390/cells9122653 · Cited by 258
Mitochondrial localization, import, and mitochondrial function of the androgen receptor
Bajpai, P., Koc, E., Sonpavde, G., Singh, R., & Singh, K. K. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.006727 · Cited by 99
“Our discovery of AR localization into mitochondria may be central to nongenomic signaling in prostate cancer as the depletion of mtDNA has been shown to induce epigenetic modulation of miRNAs (54) and the activation of CREB (55), NF- B (56), and other pathways (57) affecting cell survival and proliferation (11).”
BackgroundPiombino, C., Pipitone, S., Tonni, E., Mastrodomenico, L., Oltrecolli, M., Tchawa, C., Matranga, R., Roccabruna, S., D’Agostino, E., Pirola, M., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25094624 · Cited by 15
Peinetti, N., Cuello Rubio, M. M., Sosa, L. D. V., Scalerandi, M. V., Alasino, R. V., Peyret, V., Nicola, J. P., Beltramo, D. M., Quintar, A. A., & Maldonado, C. A. (2020) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2020.119985 · Cited by 7
Metadata
- Authors
- Leung, J. K., & Sadar, M. D.
- Venue
- Frontiers in Endocrinology
- Publisher
- Frontiers Media SA
- Published
- 2017-01-17
- Volume
- 8
- Pages
- 2-2
- ISSN
- 1664-2392 (ISSN-L)
- OpenAlex
- W2573527772
- Cited by
- 151
- References
- 20
- FWCI
- 9.52
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.